You have read all your free articles, to continue reading subscribe to read the rest of this content.
AstraZeneca has made a preliminary approach to Gilead Sciences about a potential merger, according to Bloomberg. AstraZeneca informally contacted Gilead last month to gauge its interest in a possible tie-up asking not to be identified because the details are private, reports Bloomberg. AstraZenecAlready a subscriber Login You have read all…
The acquisition of Division By Zero AB expands Brighter's IP portfolio with unique technology for, among other things, feedback human response to targeted stimuli. Brighter has offered to acquire 100% stake in Division By Zero through a share issue equivalent to 2.70 shares in Brighter per 1 sharAlready a subscriber…
AstraZeneca plans to acquire the rights to Actavis' branded respiratory business in the U.S. and Canada for an initial consideration of $600 million on completion and low single-digit royalties above a certain revenue threshold. When the transaction is finalized, AstraZeneca will own the develoAlready a subscriber Login You have read…
Pfizer has acquired Allergan for more than $150 billion, a deal that will create the world's biggest drug maker. The deal, the largest ever in the healthcare sector and involves Pfizer paying with 11.3 of its shares for each Allergan share. There will also be a small cash component, accounting Already a…
